Engine Biosciences is a venture-backed biotechnology company at the forefront of network biomedicine. They integrate proprietary machine learning algorithms (NetMAPPR®) and high-throughput wet lab validation (CombiGEM™) to decipher complex disease biology and accelerate the discovery of novel precision medicine therapies. Their primary focus is on oncology, particularly targeting genetically defined patient populations with high unmet medical needs. By identifying and validating novel drug targets and biomarkers, Engine Biosciences aims to develop impactful treatments that improve patient outcomes.
Serves as the central hub for research and development, corporate strategy, and operational management. Key activities include computational biology, wet-lab experimentation, and drug discovery program leadership.
Located within Biopolis, Singapore's world-class biomedical sciences research park, providing access to state-of-the-art facilities, a rich scientific ecosystem, and opportunities for collaboration.
A dynamic, innovative, and collaborative environment driven by a passion for scientific discovery and a commitment to translating research into impactful medicines. The culture emphasizes interdisciplinary teamwork, intellectual rigor, and a fast-paced startup mentality.
The Singapore HQ leverages the nation's strong government support for biotech, access to diverse talent, and its position as a gateway to Asia-Pacific markets and clinical research opportunities.
Engine Biosciences operates with a significant presence in two key global biotech hubs: Singapore, serving as its R&D and corporate headquarters, and San Francisco, USA, facilitating its North American operations, partnerships, and clinical development. This dual footprint allows them to leverage diverse talent pools, research ecosystems, and strategic market access in both Asia-Pacific and North America.
3 Biopolis Drive, #04-11/12, Synapse
Singapore
Singapore
Address: MBC BioLabs, 953 Indiana St, San Francisco, CA 94107, USA (Typical for biotech startups; specific suite may vary or be part of a shared lab space)
To engage with the extensive network of pharmaceutical companies, research institutions, clinical sites, and venture capital in one of the world's leading biotech clusters.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Engine Biosciences' leadership includes:
Engine Biosciences has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major, widely announced executive hires or departures at Engine Biosciences in the last 12-18 months. The core leadership team appears to have remained consistent, focusing on advancing their pipeline.
Discover the tools Engine Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Engine Biosciences likely utilizes common corporate email formats. Based on industry standards and company size, the most probable format is [first_initial][last]@[companydomain].com or [first].[last]@[companydomain].com.
[first_initial][last]@enginebio.com
Format
jlu@enginebio.com
Example
80%
Success rate
Business Wire • March 19, 2024
Engine Biosciences announced that the first patient has been dosed in its Phase 1 clinical trial of ENB-201, a targeted therapy for solid tumors characterized by KRAS/TP53 co-mutations. This marks a significant milestone in advancing their lead oncology program....more
PR Newswire • January 23, 2024
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to Engine Biosciences' ENB-201 for the treatment of adult patients with KRAS/TP53 co-mutated solid tumors. This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need....more
BioSpace • September 14, 2023
Engine Biosciences presented compelling preclinical data for its lead candidate, ENB-201, at the American Association for Cancer Research (AACR) Special Conference. The data showed significant anti-tumor activity in models of cancers with KRAS/TP53 co-mutations, a patient population with limited treatment options....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Engine Biosciences, are just a search away.